Pan-India diagnostics chain: 212 labs, 5,000+ collection centres across 750+ towns, plus African operations.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 41 |
| Reserves | 513 | 696 | 876 | 978 | 1.1k | 1.3k | 1.4k | 1.5k |
| Borrowings | 67 | 112 | 379 | 266 | 197 | 204 | 201 | 232 |
| Other Liabilities | 160 | 181 | 256 | 240 | 254 | 324 | 359 | 393 |
| Total Liabilities | 750 | 1.0k | 1.5k | 1.5k | 1.5k | 1.9k | 2.0k | 2.1k |
| AssetsFixed Assets | 296 | 343 | 1.1k | 1.1k | 1.2k | 1.4k | 1.6k | 1.6k |
| CWIP | 3 | 0 | 6 | 20 | 0 | 0 | 0 | 0 |
| Investments | 14 | 10 | 16 | 15 | 55 | 71 | 21 | 142 |
| Other Assets | 437 | 647 | 440 | 340 | 316 | 341 | 399 | 395 |
| Total Assets | 750 | 1.0k | 1.5k | 1.5k | 1.5k | 1.9k | 2.0k | 2.1k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 90 | 215 | 249 | 253 | 247 | 264 | 263 | 351 |
| Cash from Investing | 36 | -104 | 63 | -736 | 48 | -89 | -199 | -223 |
| Cash from Financing | -118 | -55 | -33 | 163 | -292 | -181 | -87 | -115 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 67 | 179 | 221 | 223 | 195 | 200 | 196 | 300 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (237.5×) and current (59.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10.1% growth and a 59× exit, ₹545 only delivers your return if you pay ₹377. The price is currently baking in 18% growth.
EPS grows 10.1%/yr for 5 years, then fades to 6% over 2, exits at 59×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.1% | 10.10 |
| FY28 | 10.1% | 11.12 |
| FY29 | 10.1% | 12.24 |
| FY30 | 10.1% | 13.47 |
| FY31 | 10.1% | 14.84 |
| FY32 | 8.0% ·fade | 16.03 |
| FY33 | 6.0% ·fade | 16.99 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.